Today's Rundown AACR: After blood cancer successes, CAR-T treatments see inroads for solid cancers AACR: Apexigen, BMS steal the show with promising I-O combo in pancreatic cancer Novartis ponies up $310M for IFM Therapeutics’ inflammation-focused unit [Sponsored] Biotech Companies Explore Alternative Strategies to Fund Growth Settlement set to sling Soon-Shiong out of biotech investment AACR: TG Therapeutics' umbralisib shrinks tumors in 52% of lymphoma patients CIC raises £150M to back startups at U.K. R&D hot spot Scott Gottlieb reflects on his tenure before joining the club of ex-FDA chiefs Pfizer, Novartis-backed British biotech Artios nabs Eli Lilly, AstraZeneca R&D veteran SpringWorks nets $125M to propel desmoid tumor, neurofibroma programs AACR: Chi-Med, AstraZeneca's savolitinib helps some Tagrisso-resistant EGFR lung cancer patients Featured Story | | | Sunday, March 31, 2019 CAR-T has seen a host of successes in blood cancers, but translating that into solid tumors has proven much more difficult. Now, early data out of the AACR cancer conference (and all the caveats that brings) may be offering some hope for that direction. |
|
|
Top Stories Monday, April 1, 2019 California biotech Apexigen said during the annual American Association for Cancer Research meeting that a combination of its CD40-activating antibody with Bristol-Myers Squibb’s PD-1 inhibitor Opdivo and chemotherapy shrunk tumors in 20 out of 24 patients with pancreatic cancer. Monday, April 1, 2019 Novartis is picking up one clinical-stage and two preclinical NLRP3 antagonist programs in its acquisition of IFM Therapeutics' inflammation-centered subsidiary. Monday, April 1, 2019 Deloitte discusses how biotech companies are exploring alternative strategies to fund growth including IPOs, collaborative arrangements, and share-based payment arrangements. Monday, April 1, 2019 Patrick Soon-Shiong’s NantCell could lose its controlling stake in Precision Biologics through a legal settlement. The proposed settlement would effectively erase NantCell’s investment to clear up a case alleging Soon-Shiong improperly withdrew $47 million from Precision Biologics. Monday, April 1, 2019 TG Therapeutics’ PI3K delta inhibitor, umbralisib, put up encouraging phase 2b data in marginal zone lymphoma, shrinking tumors in more than half of the patients followed long enough to be evaluated. Of these patients, nearly one-fifth were in complete remission, that is, their cancer was undetectable after treatment. Monday, April 1, 2019 Cambridge Innovation Capital has raised £150 million ($196 million) to invest in startups emerging from a U.K. life sciences research hot spot. The financing will support existing portfolio companies such as Bicycle and Carrick Therapeutics and equip CIC to back additional businesses. Friday, March 29, 2019 With just one week left to go in his time as FDA commissioner, Scott Gottlieb described the serendipity of being able to lead the agency while it’s “writing the modern rules.” Monday, April 1, 2019 DNA damage response specialist Artios Pharma is the latest biotech to call a pharma executive into the startup fold as it poaches Ian Smith, M.D., as its new chief medical officer. Monday, April 1, 2019 SpringWorks Therapeutics raised $125 million in its series B to advance its two lead candidates, both of which are in development for noncancerous tumors: a gamma-secretase inhibitor for desmoid tumor and a MEK inhibitor for neurofibromatosis type 1. Sunday, March 31, 2019 AstraZeneca’s Tagrisso has taken the EGFR lung cancer market by storm, but some patients develop resistance to the therapy. Enter Chi-Med and its MET inhibitor, savolitinib. Resources Sponsored by: USDM Life Sciences The year’s biggest compliance and technology trends in life sciences. Learn about the latest trends impacting the biotech, medical device and pharmaceutical industries. Sponsored by: Eurofins Discovery Learn how to utilize allosteric modulation to maximize its full potential in drug discovery programs. Download this white paper to learn more. Sponsored by: BioAnalytix, Inc. Discussion of the potential for improving biologic drug development success through earlier, strategic application of advanced mass spectrometry, because currently, with most biologic drugs, including gene therapies, failures are realized in late-stage development, after substantial investment has been made in a candidate. Sponsored by: PointCross Life Sciences Clinical trials and biomarker data from patients when unified, harmonized, and made searchable; is a rich, reliable and controlled resource for research. This paper sets out the requirements for a Translational and Biomarker Research Workbench for scientists using the experiences from use of Xbiom™ at BioPharma. Sponsored by: Unchained Labs Download this whitepaper to learn more! Sponsored by: Patheon, part of Thermo Fisher Scientific Is Flow Chemistry right for your API Development? Sponsored by: Veradigm Real-World case study by Veradigm suggests that new medications specifically approved for the treatment of systolic heart failure may be underutilized despite being important advances in patient care. Sponsored by: Outer Edge Technology Software end of life puts you at risk for data breaches, business disruption and liability. Support for Microsoft SQL Server 2008/2008 R2 and Windows Server 2008/2008 R2 ends on July 9, 2019 and January 14, 2020, respectively. Learn how you can turn these risks into a strategic business advantage. Sponsored by: AlphaSense From new regulations to drug pricing and the latest M&A deals, learn how AI is making it easier for competitive intelligence to uncover the insights they need to stay ahead of the curve. Sponsored by: InterSystems Analytics using patients’ real-time longitudinal laboratory results, and claims data, yielded higher value information and new revenue streams for TriCore reference laboratories. Sponsored by: InterSystems Whitepaper on leveraging normalized real-world patient data to streamline clinical trials, reduce delays and lower costs. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. Drug Development Immersion April 3-4, 2019 | Philadelphia, PA BioBasics: Biotech For The Non-Scientist May 8-9, 2019 | New York, NY Drug Development Immersion May 16-17, 2019 | Boston, MA 2019 BIO International Convention June 3-6, 2019 | Philadelphia, PA FierceBiotech Executive Breakfast at BIO 2019 – Getting Real: The Changing Tide on Real-World Evidence in Drug Development June 5, 2019 | Philadelphia, PA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register and start preparing Today! | 